Results 161 to 170 of about 21,488 (194)

Drug‐eluting stent coatings

WIREs Nanomedicine and Nanobiotechnology, 2009
AbstractThis paper reviews the development of coronary stents from a polymer scientist's view point, and presents the first results of an interdisciplinary team assembled for the development of new stent systems. Poly(styrene‐b‐isobutylene‐b‐styrene) block copolymer (SIBS), a nanostructured thermoplastic elastomer, is used in clinical practice as the ...
Judit E, Puskas, Lyn G, Muñoz-Robledo, Robert A, Hoerr, John, Foley, Steven P, Schmidt, Michelle, Evancho-Chapman, Jinping, Dong, Chris, Frethem, Greg, Haugstad   +8 more
openaire   +2 more sources

Drug-eluting stents: a reappraisal

Heart, 2010
The introduction of drug-eluting stents (DES) in 2002 revolutionised the field of percutaneous coronary intervention (PCI), by significantly reducing rates of restenosis when compared to bare-metal stents (BMS).1 Following this there was a rapid and unprecedented uptake in their use, such that within a matter of years they were used in approximately 80–
Garg, Scot, Serruys, PWJC (Patrick)
openaire   +2 more sources

Repeated drug-eluting stent implantation for drug-eluting stent restenosis: The same or a different stent

American Heart Journal, 2007
Currently, little data are available on the management of drug-eluting stent (DES) restenosis. Drug resistance may play a role in its etiology.We identified all cases of either sirolimus-eluting or paclitaxel-eluting stent restenosis treated with repeated DES implantation.
Cosgrave John, Melzi Gloria, Corbett Simon, Biondi-Zoccai Giuseppe G. L., Babic Rade, Airoldi Flavio, Chieffo Alaide, Sangiorgi Giuseppe M., Montorfano M, Michev Iassen, Carlino Mauro, Colombo Antonio   +11 more
openaire   +4 more sources

Drug-Eluting Stents, Restenosis and Revascularization

Herz Kardiovaskuläre Erkrankungen, 2007
Several meta-analyses have demonstrated the superiority of drug-eluting stents (DES) in reducing the incidence of restenosis, target vessel revascularization and target lesion revascularization compared to their predecessor, the bare-metal stent. In comparing Cypher and Taxus stents, the two most recent meta-analyses have given the edge to the Cypher ...
Ramcharitar, SH (Steve), Gaster, AL, Daemen, Joost, Serruys, PWJC (Patrick)   +3 more
openaire   +3 more sources

Drug-eluting stents for drug-eluting stent restenosis

Coronary Artery Disease, 2014
Sebastian, Kufner, Adnan, Kastrati
openaire   +2 more sources

Risk of Stent Thrombosis Among Bare-Metal Stents, First-Generation Drug-Eluting Stents, and Second-Generation Drug-Eluting Stents

JACC: Cardiovascular Interventions, 2013
Tomohisa Tada, Robert A Byrne, Lamin A KING   +2 more
exaly  

Inhibition of Neointima Formation by a Novel Drug-Eluting Stent System That Allows for Dose-Adjustable, Multiple, and On-Site Stent Coating

Arteriosclerosis, Thrombosis, and Vascular Biology, 2005
Rainer Wessely, Michael Vogeser, Stefan Milz   +2 more
exaly  

Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial

Lancet, The, 2013
Robert A Byrne, Julinda Mehilli, Susanne Pinieck   +2 more
exaly  

Drug-eluting stents

2012
openaire   +1 more source

Drug-Eluting Stents Are Safe

Clinical Pharmacology & Therapeutics, 2009
Garg, Scot, Serruys, PWJC (Patrick)
openaire   +3 more sources